Linda Ertl

C5a Receptor (CD88) Blockade Protects against MPO-ANCA GN

Hong Xiao, Daniel J. Dairaghi, Jay P. Powers et al. · Journal of the American Society of Nephrology · 2013 · 346 citations · Full text

Immunology, Immune Regulation, Immunologic Mechanism +21

Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease

Matthew J. Walters, Yu Wang, Trageen Baumgart et al. · Journal of Pharmacology and Experimental Therapeutics · 2010 · 158 citations

Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

Pirow Bekker, Daniel J. Dairaghi, Lisa Seitz et al. · PLoS ONE · 2016 · 144 citations · Full text

Immunology, Potent C5ar Antagonist, Receptor Inhibitor +21

CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice

Timothy J. Sullivan, Zhenhua Miao, Daniel J. Dairaghi et al. · American Journal of Physiology-Renal Physiology · 2013 · 86 citations · Full text

Receptor 2, Immunology, Insulin Signaling +18

Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cells

İhsan Ekin Demir, Kristina Kujundzic, Paulo L. Pfitzinger et al. · Proceedings of the National Academy of Sciences · 2016 · 82 citations · Full text